Clinical Study on the Efficacy and Safety of BAT5906 Injection

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 26, 2020

Primary Completion Date

September 6, 2022

Study Completion Date

September 6, 2022

Conditions
Wet Age-related Macular Degeneration
Interventions
DRUG

2.5mg of BAT5906

Specification: 2.5mg of BAT5906

DRUG

4mg of BAT5906

Specification: 4mg of BAT5906

Trial Locations (16)

100730

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

Unknown

Eye Hospital of China Academy of Chinese Medical Sciences, Beijing

Peking University First Hospital, Beijing

The First Affiliated Hospital of Bengbu Medical College, Bengbu

Zhejiang Provincial People's Hospital, Hangzhou

Jieyang People's Hospital, Jieyang

The First Hospital of Jilin University, Jilin

he Affiliated Eye Hospital of Nanchang University, Nanchang

Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing

The Affiliated Hospital of Qingdao University, Qingdao

Joint Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong, Shantou

West China Hospital of Sichuan University, Sichuan

Wenzhou Medical University Affiliated Optometry Hospital, Wenzhou

The Second Xiangya Hospital of Central South University, Xiangya

Henan Provincial Eye Hospital, Zhengzhou

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

Sponsors
All Listed Sponsors
lead

Bio-Thera Solutions

INDUSTRY